reuters.com

EyePoint’s Duravyu fails late-stage trial; FDA approval path uncertain

EyePoint Pharmaceuticals logoEyePoint Pharmaceuticals
Sig3.35Sen-6.40Env0.00Soc-0.85Gov-1.20

EyePoint said its Duravyu failed a late-stage trial to show it was not meaningfully worse than Eylea in preserving vision, with unusual cases in the Duravyu group. Approval depends on the pivotal study and a potentially tougher single-trial path. Shares fell to about $4.16, and the company plans an FDA filing in early 2027 pending a second late-stage trial.

Coverage (1)

ABOUT

What is Fimmer?

Most feeds treat all company headlines the same. An executive interview, an office closure, stock analysis, and a data breach can sit side by side with no sense of scale. Fimmer ranks coverage by what matters, so important events stand out and signals are prioritised over noise. We cluster related company news and score each story using a range of metrics, so you see the most crucial stories first.

SCORING

What do the scores mean?

Significance (0–10) measures the scale of the real-world impact. Sentiment and ESG (−10 to +10) indicate the tone of the coverage and whether the change relates to environmental, social, or governance factors. Together, these scores help distinguish meaningful developments from routine company news. More information about our scoring methodology can be found on our About page.

DISCOVERY

Explore more on Fimmer

Search more than 10,000 public companies, browse the company index, explore their scores, and read the coverage behind them, with our core features available to everyone for free.

For more advanced features, Pro gives you access to dynamic feeds, custom sorting, and more ways to track the companies that matter to you.

More with Pro